Evaluation of aerosols of prostaglandins E1 and E2 as bronchodilators.
D000328:Adult; D000336:Aerosols; D000368:Aged; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D001991:Bronchitis / Q000188:drug therapy / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000494:pharmacology*; D002245:Carbon Dioxide / Q000097:blood; D002986:Clinical Trials as Topic; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008170:Lung Compliance / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D010993:Plethysmography, Whole Body; D011453:Prostaglandins / Q000494:pharmacology* / Q000627:therapeutic use; D011674:Pulse / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D013997:Time Factors; D014692:Ventilation-Perfusion Ratio
D000336:Aerosols; D001993:Bronchodilator Agents; D011453:Prostaglandins; D002245:Carbon Dioxide; D010100:Oxygen